UK-based Fishawack Health reorganized business operations as a leading global commercialization partner for the life sciences industry in response to client demand for a more agile, integrated service offering, which is heightened by the pandemic-fueled shifts in the healthcare landscape.
If you are not happy with the results below please do another search
50 search results for:
A federal judge dismissed Catalyst Pharmaceuticals’ lawsuit against the U.S. Food and Drug Administration regarding the approval of a rival drug for a rare autoimmune disease from New Jersey-based Jacobus Pharmaceutical.
Ironwood Pharmaceuticals initiated an internal organizational restructuring that includes cutting up to 100 full-time employees from payroll following a review of unblinded data from the company’s Phase III trials for IW-3718-302, which show that the drug failed to reduce the severity of heartburn in patients with refractory gastroesophageal reflux disease (GERD).
A federal appeals court threw out an order that required AbbVie Inc. and a partner to disgorge $448 million in profit, in antitrust litigation accusing the North Chicago-based drug manufacturer of trying to illegally keep generic versions of the testosterone replacement product AndroGel off the market.
With global attention on gender and racial inequities this year, the Healthcare Businesswomen’s Association (HBA) is proud to recognize BD (Becton, Dickinson and Company) GSK, Surgical Care Affiliates and Walgreens Boots Alliance with 2020 ACE Awards for exemplary workplace initiatives that are working to close the gender and racial inequities in the healthcare and life sciences industry.
Oxford University will study whether the world’s best-selling prescription medicine adalimumab was an effective treatment for Covid-19 patients in the latest effort to repurpose existing drugs as potential coronavirus therapies.
Timothy Ray Brown, the first person known to be cured of HIV when he had a unique type of bone marrow transplant, died in California after relapsing with cancer.
Results from an early safety study of Moderna Inc.’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said.
Regeneron Pharmaceuticals Inc.’s experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients.
Germany’s CureVac NV started a mid-stage study testing the company’s experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter of 2020.